Literature DB >> 20660694

Colistin dosing and nephrotoxicity in a large community teaching hospital.

C Andrew Deryke1, Amanda J Crawford, Nizam Uddin, Mark R Wallace.   

Abstract

Thirty adult patients who received intravenous colistin (5.1 ± 2.4 mg/kg/day) were reviewed to evaluate dosing with respect to nephrotoxicity, which occurred in 10 (33%) patients within the first 5 days of treatment. Excessive colistin dosing was frequent (47%), often (71%) resulted from the use of actual body weight in obese patients, and was associated with higher rates of nephrotoxicity (80% versus 30%, P = 0.019).

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20660694      PMCID： PMC2944569          DOI： 10.1128/AAC.01707-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.

Authors:  M E Evans; D J Feola; R P Rapp
Journal:  Ann Pharmacother       Date:  1999-09       Impact factor: 3.154

2.  Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration.

Authors:  J Li; C R Rayner; R L Nation; R Deans; R Boots; N Widdecombe; A Douglas; J Lipman
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 3.  Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.

Authors:  Jian Li; Roger L Nation; John D Turnidge; Robert W Milne; Kingsley Coulthard; Craig R Rayner; David L Paterson
Journal:  Lancet Infect Dis       Date:  2006-09       Impact factor: 25.071

4.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

5.  Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  A S Levin; A A Barone; J Penço; M V Santos; I S Marinho; E A Arruda; E I Manrique; S F Costa
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

6.  Nephrotoxicity of intravenous colistin: a prospective evaluation.

Authors:  Matthew E Falagas; Konstantinos N Fragoulis; Sofia K Kasiakou; George J Sermaidis; Argyris Michalopoulos
Journal:  Int J Antimicrob Agents       Date:  2005-11-08       Impact factor: 5.283

Review 7.  Colistin in the 21st century.

Authors:  Roger L Nation; Jian Li
Journal:  Curr Opin Infect Dis       Date:  2009-12       Impact factor: 4.915

8.  Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis.

Authors:  Jian Li; Kingsley Coulthard; Robert Milne; Roger L Nation; Steven Conway; Daniel Peckham; Christine Etherington; John Turnidge
Journal:  J Antimicrob Chemother       Date:  2003-10-29       Impact factor: 5.790

9.  Toxicity after prolonged (more than four weeks) administration of intravenous colistin.

Authors:  Matthew E Falagas; Michael Rizos; Ioannis A Bliziotis; Kostas Rellos; Sofia K Kasiakou; Argyris Michalopoulos
Journal:  BMC Infect Dis       Date:  2005-01-10       Impact factor: 3.090

10.  Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients.

Authors:  Nikolaos Markou; Haralampos Apostolakos; Christiana Koumoudiou; Maria Athanasiou; Alexandra Koutsoukou; Ioannis Alamanos; Leonidas Gregorakos
Journal:  Crit Care       Date:  2003-07-28       Impact factor: 9.097
View more
  43 in total

1.  Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill.

Authors:  Ami F Mohamed; Ilias Karaiskos; Diamantis Plachouras; Matti Karvanen; Konstantinos Pontikis; Britt Jansson; Evangelos Papadomichelakis; Anastasia Antoniadou; Helen Giamarellou; Apostolos Armaganidis; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

Review 2.  A review on colistin nephrotoxicity.

Authors:  Atefeh Ordooei Javan; Shervin Shokouhi; Zahra Sahraei
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

3.  Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients.

Authors:  Timothy P Gauthier; William R Wolowich; Arathi Reddy; Ennie Cano; Lilian Abbo; Laura B Smith
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

4.  Evaluation of Risk Factors for Intravenous Colistin Use-related Nephrotoxicity.

Authors:  Iftihar Koksal; Selcuk Kaya; Eda Gencalioglu; Gurdal Yilmaz
Journal:  Oman Med J       Date:  2016-07

5.  The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Zakuan Z Deris; Heidi H Yu; Kathryn Davis; Rachel L Soon; Jovan Jacob; Caron K Ku; Anima Poudyal; Phillip J Bergen; Brian T Tsuji; Jurgen B Bulitta; Alan Forrest; David L Paterson; Tony Velkov; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

6.  Co-Delivery of Ciprofloxacin and Colistin in Liposomal Formulations with Enhanced In Vitro Antimicrobial Activities against Multidrug Resistant Pseudomonas aeruginosa.

Authors:  Shaoning Wang; Shihui Yu; Yuwei Lin; Peizhi Zou; Guihong Chai; Heidi H Yu; Hasini Wickremasinghe; Nivedita Shetty; Junhong Ling; Jian Li; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-08-09       Impact factor: 4.200

Review 7.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

8.  Evaluation of co-delivery of colistin and ciprofloxacin in liposomes using an in vitro human lung epithelial cell model.

Authors:  Guihong Chai; Heejun Park; Shihui Yu; Fanfan Zhou; Jian Li; Qingguo Xu; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2019-08-12       Impact factor: 5.875

9.  Variables determining the development of colistin-associated renal impairment.

Authors:  Bahadır Ceylan; Müdür Taniş; Muhammed Emin Akkoyunlu; Ahmet Çınar; Ayşe Ruhkar Kurt; Yasemin Akkoyunlu; Didem Ozkan; Hatice Kutbay Ozcelik; Turan Aslan; Muzaffer Fincancı; Şule Vatansever; Kadir İdin; Emine Guler; Harun Uysal
Journal:  Wien Klin Wochenschr       Date:  2015-04-28       Impact factor: 1.704

10.  Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium.

Authors:  Moataz M Hassan; Zied Gaifer; Ibrahim S Al-Zakwani
Journal:  Int J Clin Pharm       Date:  2018-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.